×

Access Whitepaper

First Name
Last Name
Phone Number
Thank you!
Error - something went wrong!
   

Is It Gene Therapy? Debating a Controversial Definition

September 20, 2017

In 2017, Novartis seized the spotlight by winning FDA approval of the first CAR-T immunotherapy, CTL019 (Kymriah) for acute lymphoblastic leukemia (ALL). While noteworthy in and of itself, this occurred the same week that Gilead Sciences reported its $11 billion acquisition of Kite Pharma, a leader in CAR-T immunotherapy for cancer.  
 
This opens up the conversation about the classification of new therapies employing genetic modifications. Are they all gene therapy? A quick study of the social media posts on the approval of Kymriah reveals that there are a variety of opinions on what constitutes gene therapy. And you may be surprised by some of those opinions. Read this white paper highlighting the confusion that abounds around the classification of the new CAR-T therapies. 

Previous Flipbook
Looking Ahead to 2018: Insights into Clinical Research Trends from Our Experts
Looking Ahead to 2018: Insights into Clinical Research Trends from Our Experts

In this paper, WCG thought-leaders provide insights on what they anticipate in 2018 in clinical trial techn...

Next Flipbook
Pragmatic Clinical Trials: What You Need to Know
Pragmatic Clinical Trials: What You Need to Know